ACAD ACADIA Pharmaceuticals
- 17.230
- +0.180+1.06%
ACADIA Pharmaceuticals News
UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating
ACADIA Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
ACADIA Pharmaceuticals Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
Needham: Reiterated ACADIA Pharmaceuticals (ACAD.US) rating, adjusted from buy to buy rating, target price $32.00.
ACADIA Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $32 Price Target
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $25
ACADIA Pharmaceuticals Analyst Ratings
UBS Adjusts ACADIA Pharmaceuticals Price Target to $33 From $35, Maintains Buy Rating
Morgan Stanley Cuts Price Target on ACADIA Pharmaceuticals to $30 From $40 After Failed Study of Pimavanserin in Negative Symptoms of Schizophrenia; Overweight Kept
UBS Cuts Acadia Pharma Target to $33 on Nuplazid Trial Outcome
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30.19
Mizuho Cuts Acadia to Neutral, Cites Lack of Upcoming Catalysts
Analysts' Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD)
JMP Securities Cuts ACADIA Pharmaceuticals Price Target to $39 From $44, Maintains Market Outperform Rating
RBC Cuts Price Target on ACADIA Pharmaceuticals to $30 From $35 After Phase 3 Trial of Pimavanserin Fails to Reach Primary Endpoint; Outperform Kept
Analysis
Price Target
No Data
